MedPath

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

Phase 3
Completed
Conditions
Osteoporosis, Postmenopausal
Interventions
Drug: Placebo
Registration Number
NCT00088010
Lead Sponsor
Eli Lilly and Company
Brief Summary

The purpose of this trial is to study:

* Effects of arzoxifene on bone fractures and bone mass.

* Effects of arzoxifene on getting breast cancer.

* Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke.

* Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health.

* Effects of arzoxifene on the uterus.

* The safety of arzoxifene and any side effects.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
9369
Inclusion Criteria
  • 60-85 years of age
  • Female
  • At least two years since last menstrual cycle
Exclusion Criteria
  • Abnormal or unexplained vaginal bleeding.
  • Bone disorders, other than osteoporosis or low bone mass
  • History of breast cancer, cancer of the uterus, or any cancer in the last five years (except skin cancer).
  • History of cerebral vascular accidents or venous thromboembolic events
  • Medications outlined

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2Placebo-
1Arzoxifene-
Primary Outcome Measures
NameTimeMethod
Effects of arzoxifene on bone fractures and bone mass5 years
Effects of arzoxifene on getting breast cancer5 years
The safety of arzoxifene and any side effects5 years
Secondary Outcome Measures
NameTimeMethod
Effects of arzoxifene on certain types of cardiovascular events5 years
Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health5 years
Effects of arzoxifene on the uterus5 years
Effects of arzoxifene on cognition5 years
Effects of arzoxifene on back pain5 years

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

🇺🇸

Elk Grove, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath